Screener
Viridian Therapeutics, Inc. VRDN Total Liabilities
Total Liabilities at other companies
Other financials
Where this comes from
Reported directly by Viridian Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesFairValueDisclosure.
The source filing: Viridian Therapeutics, Inc.’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 7:31 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001590750-26-000018
FAQ
- What is Viridian Therapeutics, Inc.'s total liabilities?
- Viridian Therapeutics, Inc. (VRDN) reported total liabilities of $13.69M in Q2 2026.
- How has Viridian Therapeutics, Inc.'s total liabilities changed year-over-year?
- Viridian Therapeutics, Inc.'s total liabilities decreased by 79.6% year-over-year, from $67.16M to $13.69M.
- What is the long-term trend for Viridian Therapeutics, Inc.'s total liabilities?
- Over 5 years (2020 to 2025), Viridian Therapeutics, Inc.'s total liabilities has grown at a 12.3% compound annual growth rate (CAGR), from $11.22M to $20.03M.
- What does total liabilities mean?
- The sum of all current and non-current obligations — everything the company owes to creditors, employees, governments, and other stakeholders.
Ask your AI about Viridian Therapeutics, Inc.'s total liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude